Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

CAR-T maka nnukwu B-cell Lymphoblastic leukemia (B-ALL)

    Nchịkọta

    B-ALL (Acute B-cell Lymphoblastic leukemia) bụ ụdị ọrịa leukemia na-eme ihe ike, nke na-emetụta ụmụaka na ndị okenye. N'agbanyeghị ọganihu na ọgwụgwọ chemotherapy ọdịnala, ọtụtụ ndị ọrịa na-enweta nlọghachi azụ ma ọ bụ nkwụsị ọgwụgwọ. CAR-T (Chimeric Antigen Receptor T-cell) ọgwụgwọ na-anọchite anya immunotherapy na-emebi emebi nke gosipụtara ihe ịga nke ọma dị ịrịba ama n'ịgwọ nlọghachi azụ ma ọ bụ B-ALL, na-enye olileanya maka ndị ọrịa na-enwebu oke nhọrọ ọgwụgwọ.

    Kedu ihe bụ CAR-T Therapy?

    Usoro ọgwụgwọ CAR-T bụ ọgwụgwọ dị elu, ahaziri onwe ya nke gụnyere imegharị mkpụrụ ndụ T nke onye ọrịa iji mata ma wakpo mkpụrụ ndụ kansa ọgụ. Maka B-ALL, a na-emezi mkpụrụ ndụ CAR-T ka ha lekwasị anya na CD19 antigen, protein a na-ahụkarị n'elu sel B-cell leukemia. Ozugbo etinyere ya n'ime ahụ onye ọrịa ahụ, mkpụrụ ndụ T ndị a na-emezigharị na-achọ ma bibie mkpụrụ ndụ leukemia, nke nwere ike ibute mgbaghara na-adịte aka.

    Isi uru nke ọgwụgwọ CAR-T maka B-ALL

    • Ịrụ ọrụ dị elu: Usoro ọgwụgwọ CAR-T egosila nnukwu ihe ịga nke ọma n'ịgwọ nlọghachi azụ ma ọ bụ refractory B-ALL, na-enye ọnụ ọgụgụ dị elu nke mgbapụta na ndị ọrịa na-anabataghị ọgwụgwọ ọdịnala.
    • Omume ezubere iche: Site n'ilekwasị anya na antigen CD19, ọgwụgwọ CAR-T na-elekwasị anya ma na-ebibi mkpụrụ ndụ B-ALL, na-ebelata mmebi nke anụ ahụ dị mma.
    • Ọgwụgwọ ahaziri onwe ya: Ebe ọ bụ na mkpụrụ ndụ CAR-T na-enweta site na usoro ahụ ji alụso ọrịa ọgụ nke onye ọrịa, a na-ahazi ọgwụgwọ ahụ nke ọma, na-abawanye uru ya na ibelata ihe ize ndụ nke ịjụ.
    • Mgbaghara na-adịgide adịgide: N'ọtụtụ ọnọdụ, ọgwụgwọ CAR-T emela ka mgbaghara na-adịgide adịgide, na-enye ndị ọrịa ohere ịlanarị ogologo oge na nlọghachi ole na ole.

    Usoro ọgwụgwọ

    • Nchịkọta nke cell TNzọụkwụ mbụ gụnyere ịnakọta mkpụrụ ndụ T n'ọbara onye ọrịa site na usoro a na-akpọ leukapheresis.
    • Injinia T-cell: A na-emezi mkpụrụ ndụ T nke anakọtara na ụlọ nyocha iji gosipụta chimeric antigen receptor (CAR) kpọmkwem na CD19, na-eme ka ikike ha na-elekwasị anya na sel B-ALL.
    • Infusion nke mkpụrụ ndụ CAR-T: Mgbe obere oge nke mgbasawanye cell gachara, a na-agbanyeghachi mkpụrụ ndụ CAR-T n'ime ahụ onye ọrịa site na intravenous (IV).
    • Nleba anya na mgbake: Post-infusion, a na-enyocha ndị ọrịa nke ọma maka mmetụta ndị nwere ike ime dị ka cytokine release syndrome (CRS) na neurotoxicity. Mmeghachi omume ndị a na-adịkarị mfe ijikwa, na ọtụtụ ndị ọrịa na-agbake site na enyemaka kwesịrị ekwesị.

    Kedu ihe kpatara ịhọrọ ọgwụgwọ BIOOCUS CAR-T maka B-ALL?

    • Teknụzụ ọgbara ọhụrụBIOOCUS na-eji teknụzụ na-egbutu ọnụ iji hụ na mmepụta mkpụrụ ndụ CAR-T kacha mma yana nsonaazụ onye ọrịa.
    • Otu ọkachamara ahụike: Ndị otu anyị ndị ọkachamara na hematology na immunotherapy raara onwe ha nye inye nlekọta ahaziri onwe ya na ịkwalite ọganihu nke ọgwụgwọ ọ bụla.
    • Ahụmahụ mba ụwa: Anyị na-enye ndị ọrịa si gburugburu ụwa ọgwụgwọ CAR-T, yana ndekọ ndekọ nke ọgwụgwọ na-aga nke ọma na mgbapụta ogologo oge maka ndị ọrịa B-ALL.
    • Nlekọta zuru oke: Site na nyocha mbụ site na nlekota nlekota, BIOOCUS na-enye nlekọta zuru oke, na-eme ka ndị ọrịa nweta ọgwụgwọ kachasị mma n'oge ọ bụla.

    Ihe akaebe na-ahụ maka ụlọ ọgwụ na ọnụego ihe ịga nke ọma

    Nnwale ụlọ ọgwụ na nso nso a na data ụwa n'ezie egosila na ọgwụgwọ CAR-T maka B-ALL na-enye nsonaazụ pụrụ iche, ọkachasị maka ndị ọrịa laghachiri azụ ma ọ bụ na-eguzogide ọgwụgwọ ọdịnala. Usoro ọgwụgwọ ahụ egosipụtala ọnụ ọgụgụ mgbaghara dị elu mgbe niile, yana ọtụtụ ndị ọrịa na-enweta mgbaghara zuru oke na ịnọgide na-adị ogologo oge.

    Na BIOOCUS, anyị ejirila ọgwụgwọ CAR-T gwọọ ọtụtụ ndị ọrịa nwere B-ALL nke ọma, nsonaazụ ya adịla mma nke ukwuu. Maka nghọta miri emi nke akụkọ ịga nke ọma na nsonaazụ ndụ n'ezie, biko nyochaa ihe ọmụmụ ndị ọrịa ndị a:

    Ọnọdụ ndị a na-egosipụta ikike mgbanwe nke ọgwụgwọ CAR-T maka ndị ọrịa B-NIILE, na-egosi ọ bụghị naanị ịdị irè ọgwụgwọ kamakwa ikike ya inye ndị ọrịa ohere nke abụọ na ndụ.

    Data ụlọ ọgwụ

    Ngosipụta maka CD19+20CAR-T:Ndị ọrịa nwere lymphoma na-abụghị Hodgkin B-cell

    Ọnụego otu ọnwa CR

    Ọnụego PR otu ọnwa

    Otu ọnwa ma ọ bụ ọnụego

    CRS≥3

    CRES≥3

    71.95% (59/82)

    25.6 (21/82)

    97.55 (80/82)

    12.19% (10/82)

    0

    Ngosipụta maka CD19+22CAR-T:Ọgwụgwọ nke CD19 nlọghachite na refractory nnukwu B-lymphocytic leukemia ndị ọrịa.

    Ọnụego otu ọnwa CR

    Ọnụego PR otu ọnwa

    Otu ọnwa ma ọ bụ ọnụego

    CRS≥3

    CRES≥3

    92.1% (35/38)

    7.9% (3/38)

    100% (38/38)

    15.79% (6/38)

    0

    Ngosipụta maka BCMACAR-T:Ọgwụgwọ nke nlọghachi azụ na refractory multiple myeloma

    Ọnụego otu ọnwa CR

    Ọnụego PR otu ọnwa

    Otu ọnwa ma ọ bụ ọnụego

    CRS≥3

    CRES≥3

    72.41% (21/29)

    27.59% (8/29)

    100% (29/29)

    6.9% (2/29)

    0

    Submit An Free Inquiry

    Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

    AI Helps Write